Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077659 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
A Phase 2 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03077659 is a Phase 2 study that has completed, run by NanOlogy. The registered enrollment target is 16 participants.
The verdict
NCT03077659, a Phase 2 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
Interventions
- DRUG NanoPac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077659
The ClinicalTrials.gov registry entry for NCT03077659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NanoPac® is the first listed.
NCT03077659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03077659 about?
NCT03077659 is a clinical study titled "Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer". Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
What is the current status of trial NCT03077659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-09-06. Estimated completion is 2018-10-04.
What interventions are being tested in trial NCT03077659?
The interventions under investigation include: NanoPac® (DRUG).
Who is sponsoring clinical trial NCT03077659?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.